Literature DB >> 9360550

Urocortin expression in human pituitary gland and pituitary adenoma.

K Iino1, H Sasano, Y Oki, N Andoh, R W Shin, T Kitamoto, K Totsune, K Takahashi, H Suzuki, H Nagura, T Yoshimi.   

Abstract

Urocortin is a recently identified neuropeptide of the CRF family in the mammalian brain, but its expression in human tissue has been little studied. In this study, we examined urocortin expression in human anterior pituitary gland and pituitary adenomas by RIA, high performance liquid chromatography, immunohistochemistry, messenger ribonucleic acid (mRNA) in situ hybridization, and reverse transcriptase-PCR. Immunoreactive urocortin concentrations in normal pituitary tissue extract were 103.25 +/- 39.05 ng/g wet wt (mean +/- SEM; n = 4), and their levels were all significantly higher than those in other portions of central nervous system of the same subjects. High performance liquid chromatography analysis of human pituitary extract demonstrated a single peak corresponding to that of the expected chromatographic mobility of synthetic human urocortin-(1-40). Urocortin-immunoreactive cells were detected in the anterior pituitary gland. Neither urocortin-immunoreactive nerve fibers nor cells were detected in the posterior lobe. Immunostaining in serial mirror tissue sections revealed that 76.55 +/- 3.06% of urocortin-immunoreactive cells expressed GH immunoreactivity, whereas 22.25 +/- 3.02% and less than 1% of urocortin-immunoreactive cells expressed PRL and ACTH, respectively. mRNA hybridization signals of urocortin were also detected in urocortin-immunopositive pituitary cells. The reverse transcriptase-PCR analysis demonstrated a 145-bp RNA band corresponding to that of the expected length of urocortin in all cases of normal pituitary glands examined (n = 3). We also immunostained urocortin in 52 cases of human anterior pituitary adenomas, including GH-producing adenomas (n = 14), ACTH-producing adenomas (n = 13), PRL-producing adenomas (n = 11), and nonfunctioning hormonally inactive adenomas (n = 14). No urocortin immunoreactivity was detected in these adenoma cells, except for one case of GH-producing adenoma and one case of nonfunctioning adenoma. We also performed mRNA in situ hybridization in 27 adenomas. No hybridization signals were detected in these adenomas, except in two cases. The results described above indicated that urocortin is synthesized in human anterior pituitary cells and may play an important role in biological features of normal pituitary gland, possibly as an autocrine or a paracrine regulator

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360550     DOI: 10.1210/jcem.82.11.4371

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Expression of hypothalamic corticotropin-releasing hormone-like immunoreactivity in isolated ACTH deficiency: a report of an autopsied case.

Authors:  T Mori; Y Murakami; M Nishiki; K Koshimura; H Sasano; Y Kato
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 2.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

Review 3.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

Review 4.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

5.  Urocortin hyperpolarizes stomach smooth muscle via activation of Ca2+-sensitive K+ currents.

Authors:  P S Petkova-Kirova; H S Gagov; D B Duridanova
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

6.  Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress.

Authors:  E M Fekete; Y Zhao; A Szücs; V Sabino; P Cottone; J Rivier; W W Vale; G F Koob; E P Zorrilla
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 7.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

8.  Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.

Authors:  Kazuhiro Takahashi
Journal:  Int J Endocrinol       Date:  2012-05-17       Impact factor: 3.257

Review 9.  The Role of Urocortins in Intracerebral Hemorrhage.

Authors:  Ker Woon Choy; Andy Po-Yi Tsai; Peter Bor-Chian Lin; Meng-Yu Wu; Chihyi Lee; Aspalilah Alias; Cheng-Yoong Pang; Hock-Kean Liew
Journal:  Biomolecules       Date:  2020-01-07

10.  Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health.

Authors:  Donny Janssen; Tamás Kozicz
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-12       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.